Madrigal reports prelim sales for MASH drug

More on Madrigal Pharmaceuticals

• Fast Drug Launch For Madrigal Pharmaceuticals Brings Buyout Discussion
• Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion
• Seeking Alpha | January 13, 2025

Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CONSHOHOCKEN, Pa., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 2:15 pm PT. The presentation will be webcast live and can be accessed here or by visiting Madrigal’s Investor Relations Site, Events and Presentations. About Madrigal Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering no

Yahoo | January 3, 2025

Exploring Three High Growth Tech Stocks In The United States

Over the last 7 days, the United States market has remained flat, yet it is up 25% over the past year with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies with strong innovation potential and solid financial health that can capitalize on these favorable conditions.

Yahoo | December 25, 2024

Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Profit Outlook

Madrigal Pharmaceuticals, Inc. ( NASDAQ:MDGL ) is possibly approaching a major achievement in its business, so we would...

Yahoo | December 18, 2024

Madrigal Pharmaceuticals price target raised to $427 from $415 at JMP Securities

JMP Securities raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $427 from $415 and keeps an Outperform rating on the shares as part of a broader note on Biotechnology. The firm highlighted key upcoming catalysts for its coverage universe over the next 12 months, ahead of what is shaping up to be a “busy” 2025, and noted that it still has several events expected between now and the end of the year which could provide a reason for “cheer” this holiday season. Published first on

Yahoo | December 6, 2024

3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move

When a company's shares shoot up 82% in 12 months, investors clearly think it's a good time to be a shareholder -- and that's exactly what's happened to the stock of Madrigal Pharmaceuticals (NASDAQ: MDGL). When it was approved in March 2024, Rezdiffra became the only medicine approved by the Food and Drug Administration (FDA) to treat metabolic-associated steatohepatitis (MASH), a disease that's characterized by fatty deposits on the liver, toughening and stiffening of liver tissue (fibrosis), and eventually scarring of the liver (cirrhosis). Since then, Madrigal has been focused on getting more patients on treatment so that it can generate sales.

Yahoo | November 23, 2024

Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy?

Is it a good or bad thing when a stock experiences a golden cross technical event?

Yahoo | November 22, 2024

Why Is Madrigal Pharmaceuticals, Inc. (MDGL) Among the Worst Performing Biotech Stocks in 2024?

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look at where Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) stands against the other biotech stocks. Biotechnology Stocks: Navigating Volatility Amid Market Fluctuations and Industry Growth Biotechnology stocks are among the most volatile in the market […]

Yahoo | November 21, 2024

The first MASH drug could open the door for others — including GLP-1s

With only one approved drug on the market, companies like Inventiva Pharma are advancing MASH drugs and seeking a competitive edge.

Yahoo | November 18, 2024

John Paulson's Strategic Moves in Q3 2024: A Focus on Anglogold Ashanti PLC

Insights into the Investment Shifts of a Hedge Fund Titan

Yahoo | November 15, 2024